| Specificity |
This product is specific to FMC63 scFv and CARs derived from FMC63 scFv. |
| Host Species |
Rabbit |
| Immunogen |
FMC63 scFv |
| Conjugate |
iFluor 647 |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| Flow Cytometry |
1:50 |
|
| Form |
Liquid |
| Storage Buffer |
Supplied in PBS (pH 7.2), containing 10 mg/ml BSA, 0.03% ProClin300 and 50% glycerol. |
| Storage Instructions |
Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification |
Protein A affinity column |
| Isotype |
Rabbit IgG, κ |
| Clonality |
Monoclonal |
| Clone ID |
24B2 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
![MonoRab™ Anti-FMC63 Antibody (24B2) [iFluor 647], MAb, Rabbit](/product/documents/down?doc_name=A02330_CAR.jpg&file=scm_files/productFile_notes/2024/11/08/6690a4f2-772b-4f20-87c7-19898fff02cc.jpg "MonoRab™ Anti-FMC63 Antibody (24B2) [iFluor 647], MAb, Rabbit")
The detection of PBMCs with or without FMC63 CAR-T cells using MonoRab™ Anti-FMC63 Antibody (24B2) [iFluor 647], mAb, Rabbit (GenScript, A02330) demonstrated minimal nonspecific binding to PBMCs and specific recognition of FMC63-expressing CARs.
| Target Background |
The FMC63 scFv (single-chain variable fragment) is a key component in many chimeric antigen receptor (CAR) designs, particularly in CAR-T cell therapies. Derived from a murine monoclonal antibody, FMC63 specifically targets human CD19, a cell surface protein highly expressed on B-cells, including malignant B-cells in B-cell leukemias and lymphomas. This scFv fragment is engineered by fusing the variable regions of the heavy and light chains of the antibody, preserving the antigen-binding capability while significantly reducing its size. This smaller, single-chain format enhances its integration into CAR constructs, enabling the recognition and destruction of CD19-positive cells by CAR-T cells. FMC63-based CARs are widely used in immunotherapy, particularly in FDA-approved treatments for B-cell malignancies, such as Kymriah® and Yescarta®. |
| Synonyms |
FMC63; FMC63 scFv; FMC63-scFv; FMC63-CD19; Anti-CD19 (FMC63) CAR; Anti-CD19 (FMC63) |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
